Andere talen Dicot Pharma AB

Aandelen

slotkoers NORDIC GROWTH MARKET Andere beurzen 00:00:00 27-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,464 ^SEK	-16,70%		+14,00%	+45,91%

06/06	Dicot Pharma AB ontwikkelt LIB-01 tot een medicijn met een nieuwe potentie en betere eigenschappen dan de momenteel beschikbare medicijnen	CI
06/05	Dicot AB (publ) rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Dicot Pharma: Experts from Dicot Pharma's clinical study behind submitted abstract	19/06
Experts from Dicot Pharma's clinical study behind submitted abstract	18/06
LIB-01 appears to affect metabolic diseases and Dicot Pharma files new patent application	06/06
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs	06/06
Today Dicot AB becomes Dicot Pharma AB	30/05
Dicot presents interim report Q1 2024	06/05
Dicot Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Dicot AB has Changed its Name to Dicot Pharma AB	06/05
Good safety and improved erectile function reported from Dicot's phase 1 study	23/04
Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	23/04
Dicot in preparation for clinical phase 2a trial	12/04
Reporting from Dicot's phase 1 study end of April	05/04
BioStock: Dicot's phase I study fully recruited	14/03
Recruitment completed in Dicot's phase 1 trial	11/03
Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial	11/03
Dicot's CEO tells BioStock: "Several prominent people want to be part of the journey"	29/02
Dicot AB Year-End Report 2023	26/02
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/02
BioStock: Good safety profile for Dicot's LIB-01	26/01
Positive results from the first part of Dicot's phase 1 study	23/01

Geen resultaten voor deze zoekopdracht